Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

W Shen, CL De Hoyos, MT Migawa, TA Vickers… - Nature …, 2019 - nature.com
W Shen, CL De Hoyos, MT Migawa, TA Vickers, H Sun, A Low, TA Bell III, M Rahdar
Nature biotechnology, 2019nature.com
The molecular mechanisms of toxicity of chemically modified phosphorothioate antisense
oligonucleotides (PS-ASOs) are not fully understood. Here, we report that toxic gapmer PS-
ASOs containing modifications such as constrained ethyl (cEt), locked nucleic acid (LNA)
and 2′-O-methoxyethyl (2′-MOE) bind many cellular proteins with high avidity, altering
their function, localization and stability. We show that RNase H1–dependent delocalization
of paraspeckle proteins to nucleoli is an early event in PS-ASO toxicity, followed by …
Abstract
The molecular mechanisms of toxicity of chemically modified phosphorothioate antisense oligonucleotides (PS-ASOs) are not fully understood. Here, we report that toxic gapmer PS-ASOs containing modifications such as constrained ethyl (cEt), locked nucleic acid (LNA) and 2′-O-methoxyethyl (2′-MOE) bind many cellular proteins with high avidity, altering their function, localization and stability. We show that RNase H1–dependent delocalization of paraspeckle proteins to nucleoli is an early event in PS-ASO toxicity, followed by nucleolar stress, p53 activation and apoptotic cell death. Introduction of a single 2′-O-methyl (2′-OMe) modification at gap position 2 reduced protein-binding, substantially decreasing hepatotoxicity and improving the therapeutic index with minimal impairment of antisense activity. We validated the ability of this modification to generally mitigate PS-ASO toxicity with more than 300 sequences. Our findings will guide the design of PS-ASOs with optimal therapeutic profiles.
nature.com